Guidance on the use of long‑acting insulin analogues for the treatment of diabetes – insulin glargine

NICE technology appraisal guidance [TA53] Published date:

NICE has recommended insulin glargine as an option for people with type 1 diabetes. For people with type 2 diabetes who need to take insulin, NICE has recommended that insulin glargine should be an option only if the person:

  • needs help with his or her insulin injections from a carer or healthcare professional, or 
  • has repeated and unpleasant hypoglycaemic episodes that significantly affect his or her way of life, or 
  • would otherwise need to have two insulin injections to maintain background levels every day as well as having to take other diabetes medicines orally.

  • The recommendations in this technology appraisal relating to type 2 diabetes have been replaced by recommendations in the Diabetes - type 2 (update) clinical guideline published in May 2008. Please note that the recommendations in this technology appraisal relating to type 1 diabetes have not changed.

    Units for reporting HbA1c have changed from % to mmol/mol since this guidance was published. The NICE Pathway on diabetes has been changed to reflect this. The guidance is being updated and the new recommendations (to be published in 2015) will use mmol/mol.


  • Get involved